Post-COVID Myoclonus-Ataxia Syndrome: A Case Report of Successful Recovery With Intravenous Immunoglobulin (IVIG) Treatment

The SARS-CoV-2 virus responsible for COVID-19 can trigger multisystemic syndromes that persist beyond the acute infection. Among these, neurological complications have become increasingly recognized. Reported outcomes include headaches, encephalitis, encephalopathy, anosmia, ageusia, Guillain-Barré syndrome, and skeletal muscle involvement such as myalgia and myasthenia gravis. Myoclonus-ataxia syndrome has emerged as a rare post-infectious complication. We describe an immunocompetent adult who developed post-COVID-19 myoclonus-ataxia with a distinct post-infectious timeline. The patient had minimal response to corticosteroids but experienced rapid and marked recovery with intravenous immunoglobulin (IVIG). Delayed access to IVIG due to insurance limitations prolonged disease progression. This case underscores the importance of individualized treatment strategies in post-COVID neurological syndromes and highlights the impact of systemic healthcare barriers. Given the rarity of this presentation and the variable treatment responses observed, this report contributes to the understanding of post-COVID neurological complications and their management.